Biotech News

Chiesi Group Completes Acquisition of KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc. (KALV)KalVista Pharmaceuticals, Inc.2026-06-11 12:41 ESTCompany update

Positioned to Expand Patient Access and Accelerate Impact in Rare Diseases PARMA, Italy & FRAMINGHAM, Mass. --(BUSINESS WIRE)--Jun. 11, 2026-- Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, today announced the completion of its acquisition

Related news

KALVKalVista Pharmaceuticals, Inc.2026-04-29 11:00 EST

Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio

KALVKalVista Pharmaceuticals, Inc.2026-05-28 11:00 EST

KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema

View all latest news

KalVista Pharmaceuticals, Inc.

Hereditary Angioedema Company KalVista Pharmaceuticals develops and commercializes therapies for hereditary angioedema. Its lead franchise is based on oral inhibition of plasma kallikrein during acute attacks. EKTERLY EKTERLY, or sebetralstat, is the first approved oral on-demand treatment for hereditary angioedema attacks. It is...

Recent company news

KALVKalVista Pharmaceuticals, Inc.2026-06-11 12:41 EST

Chiesi Group Completes Acquisition of KalVista Pharmaceuticals

KALVKalVista Pharmaceuticals, Inc.2026-05-28 11:00 EST

KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema

KALVKalVista Pharmaceuticals, Inc.2026-04-29 11:00 EST

Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio

KALVKalVista Pharmaceuticals, Inc.2026-04-08 11:00 EST

KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

KALVKalVista Pharmaceuticals, Inc.2026-04-02 20:01 EST

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close: 26.95 USD
Market cap: 1.43B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States